For a long time, acute kidney injury (AKI) was considered to be a primarily hemodynamic condition characterized by a reduction of renal blood flow, induced by either cardiogenic or distributive (septic) shock. Consequently, all efforts to treat AKI were essentially concentrated on increasing renal flow by enhancing cardiac flow output and perfusion pressure. At the beginning of this decade, Bellomo and co-workers produced new and intriguing data in an animal model of septic AKI that undermined existing concepts. They observed that medullar and cortical renal blood flow were both maintained and even increased in septic shock, underscoring that septic AKI was a totally different physiological phenomenon than nonseptic AKI. Also, apoptosis was found to play a more important role in sepsis and septic shock than pure necrosis. Despite these findings, the role of apoptosis as a main mechanism of organ dysfunction remains topic of debate.

Keywords:
Acute kidney injury, High volume hemofiltration, Mediator removal, Septic acute kidney injury, Hemofiltration, Sepsis, Acute tubular apoptosis
1.
Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 2004;351:159–169.
2.
Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R: Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008;36:198–203.
3.
Hotchkiss RS, Swanson PE, Freeman BD et al: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230–1251.
4.
Bellomo R, Wan L, Langenberg C, May C: Septic acute kidney injury: new concepts. Nephron Exp Nephrol 2008;4:95–100.
5.
Abraham E, Singer M: Mechanisms of sepsis-induced organ dysfunction. Crit Care Med. 2007;35:2408–2416.
6.
Lerolle N, Nochy D, Guérot E, et al: Histopathology of septic shock induced renal injury: apotosis and leukocytic infiltration. Intensive Care Med 2010;36:471–478.
7.
Devarajan P: Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 2005;17:193–199.
8.
Rana A, Sathyanarayana P, Lieberthal W: Role of apoptosis of renal tubular cells in acute renal failure: therapeutic implications. Apoptosis 2001;6:83–102.
9.
Boneggio R, Lieberthal W: Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002;11:301–308.
10.
Homsi E, Janino P, de Faria JB: Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int 2006;69:1385–1392.
11.
Guo R, Wang Y, Minto AW, Quigg RJ, Cunningham PN: Acute renal failure in endotoxemia is dependant on caspase activation. J Am Soc Nephrol 2004;15:3093–3102.
12.
Mariano F, Cantaluppi V, Stella M, et al: Circulating plasma factors induce tubular and glomerular alterations in septic burns patients. Crit Care 2008;12:R42.
13.
Honore PM, Joannes-Boyau O, Boer W, Collin V: High-volume hemofiltration in sepsis and SIRS: current concepts and future prospects. Blood Purif 2009;28:1–11.
14.
Cantaluppi V, Assenzio B, Pasero D, et al: Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 2008;34:1638–1645.
15.
Bell M, SWING, Granath F, Schon S, Ekbom A, Martling CR: Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. Intensive Care Med 2007;33:773–780.
16.
Palevsky PM, Zhang JH, O’Connor TZ, et al: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20.
17.
Ridel C, Balde MC, Rondeau E, Vinsonneau C: Dose of dialysis in intensive care unit. Reanimation 2009;18:385–396.
18.
Ronco C, Cruz D, Oudemans-van-Straaten HM, Honoré PM, House A, Bin D, Gibney N: Dialysis dose in acute kidney injury: no time for therapeutic nihilism – a critical appraisal of the Acute Renal Failure Trial Network study. Crit Care 2008;12:308.
19.
Bellomo R, Cass A, Cole L, et al: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627–1628.
20.
Palevsky PM, O’Connor TZ, Chertow GM, Crowley ST, Zhang JH, Kellum JA: Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Crit Care 2009;13:310.
21.
Parmar A, Langenberg C, Wan L, May CN, Bellomo R, Bagshaw SM: Epidemiology of septic acute kidney injury. Curr Drug Targets 2009;10:1169–1178.
22.
Honore PM, Jacobs R, Boer W, Joannes-Boyau O: Sepsis and AKI: more complex than just a simple question of chicken and egg. Intensive Care Med 2011;37:186–189.
23.
Langenberg C, Bagshaw SM, May CN, Bellomo R: The histopathology of septic acute kidney injury: a systematic review. Crit Care 2008;12:R38.
24.
Bellomo R, Bagshaw S, Langenberg C, Ronco C: Pre-renal azotemia: a flawed paradigm in critically ill septic patients? Contrib Nephrol. Basel, Karger, 2007, vol 156, pp 1–9.
25.
Honore PM, Jacobs R, Joannes-Boyau O, Boer W, De Waele E, De Regt J, Collin V, Spapen HS: Septic AKl in ICU patients. Diagnosis, pathophysiology and treatment type, dosing and timing: a comprehensive review of recent and future developments. Annals of Intensive Care 2011;1: in press.
26.
Wang W, Bansal S, Falk S, Ljubanovic D, Schrier RW: Ghrelin protects mice against endotoxemia-induced acute kidney injury. Am J Physiol Renal Physiol 2009;297:F1032–F1037.
27.
Simon F, Giucidi R, Scheurle A, et al: Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial. Crit Care 2009;13:R113.
28.
Janssen van Doorn K, Spapen HS, Geers C, Diltoer M, Shabana W: Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment? Acta Anaesthesiol Scand 2008,52:1259–1264.
29.
Wen X, Murugan R, Peng Z, Kellum JA: Pathophysiology of acute kidney injury: a new perspective. Contrib Nephrol. Basel, Karger, 2010, vol 165, pp 39–45.
30.
Honore PM, Joannes-Boyau O, Boer W, Collin V, Jennes S: Continuous haemofiltration in 2009: what’s new for clinicians regarding: pathophysiology, technique to be privileged and dose to be recommended – in-depth review. Blood Purif 2009;28–135–143.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.